Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised

July 9, 2026| Source: Lancet (London, England)

Alternatives to carbapenems for the treatment of third-generation cephalosporin-resistant Enterobacterales (3GCR-E) are urgently needed to reduce the selection pressure posed by these drugs. Temocillin is a neglected narrow-spectrum β-lactam. The aim of the trial was to investigate if temocillin is non-inferior to carbapenems for the targeted treatment of bacteraemia due to 3GCR-E. This multicentre, phase 3, open-label, non-inferiority, randomised, pragmatic, investigator-initiated clinical trial was conducted in 29 Spanish hospitals. We randomly assigned patients with bacteraemia caused by 3GCR-E to receive intravenous temocillin (2 g every 8 h) or meropenem (1 g every 8 h; or ertapenem [1 g per day] if appropriate). Patients aged 18 years or older were eligible if they had monomicrobial bacteraemia due to any 3GCR-E that was susceptible to meropenem and temocillin and treatment for at least 4 days with an active intravenous drug was considered necessary. Randomisation (1:1) was stratified according to previous active drug and to source of infection; no blocks were used. The primary endpoint was clinical success (clinical cure, no need to stop or change the study drug because of adverse event or clinical failure, absence of recurrence, and survival by day 28) in all randomly assigned patients who received at least one dose of a study drug (modified intention-to-treat population [mITT]). Adverse events were assessed in the mITT population. No missing data were reported. A 10% non-inferiority margin was established. The trial was registered in ClinicalTrials.gov (NCT04478721) and is complete and closed to new participants. 334 eligible patients were enrolled between Dec 15, 2020, and Nov 29, 2024, of whom 328 were included in the mITT population (163 assigned temocillin and 165 assigned carbapenems). In 328 participants, the median age was 72 years (IQR 65-80), 106 (32%) were female, 222 (68%) were male, and the median Charlson Comorbidity Index was 2 (IQR 0-4). In the mITT population, clinical success occurred in 120 (74%) of 163 patients assigned temocillin and 121 (73%) of 165 patients assigned carbapenems (difference 0·3% [95% CI -7·7 to ∞]; non-inferiority p=0·017). Serious adverse events were reported in 31 (19%) of 163 patients assigned temocillin and 35 (24%) of 165 patients assigned carbapenems. In patients with bacteraemia caused by 3GCR-E, temocillin was non-inferior to carbapenems as targeted treatment. These findings support the use of temocillin as an effective and safe alternative to carbapenems in this setting. Instituto de Salud Carlos III.

Read the original source →

Cryoelectron tomography reveals an age-related decline in mitoribosomes that contributes to T cell dysfunction in older individuals.

Mitochondrial dysfunction drives T cell aging in mice. Yet, due to fundamental differences in T cell aging mechanisms between species, whether human T cells exhibit similar mitochondrial alterations remains unclear, with existing evidence often conflicting. Using cryoelectron tomography, we resolved the structure and spatial organization of mitochondrial ribosomes in primary human CD8 + T cells under physiological conditions. Comparative analysis with human aging models revealed an age-related r

RelB NF-κB tunes Notch2 signaling to promote IL-23-secreting solitary isolated lymphoid tissue-resident DCs critical for gut immunity.

While preserving tolerance toward commensals, dendritic cells (DCs) also orchestrate response against pathogens. The noncanonical RelB NF-κB pathway in DCs curbs tolerogenic Tregs in the intestine. Whether RelB-dependent DC regulations also impact intestinal immunity remains less clear. Here, we show that genetic ablation of RelB in DCs compromises IL-23-dependent immune response in the intestine, imparting vulnerability in Relb ΔCD11c mice to infection with Citrobacter rodentium , a

X-linked SYTL4 missense variant disrupts RAB27A-dependent vesicle trafficking and synaptic transmission in autism.

Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by impaired social communication and repetitive behaviors, with genetic studies implicating widespread synaptic dysfunction. However, the contribution of presynaptic vesicle trafficking mechanisms to ASD pathogenesis remains incompletely understood. Here, we identify synaptotagmin-like protein 4 (SYTL4), a RAB27A effector previously characterized in secretory cells, as a regulator of presynaptic function in the mammal

Folic acid prevention of neural tube defects requires retinoic acid produced by ALDH1L1.

Folic acid (FA) supplementation during pregnancy is the commonly accepted treatment to prevent neural tube defects. The mechanism by which FA prevents neural tube defects (NTDs) remains unclear. FA also prevents other developmental malformations, including alcohol-induced malformations in Fetal Alcohol Syndrome models. We show that FA acts through a metabolic link to retinoic acid (RA) signaling. Using a pax3 -knockdown Xenopus model of FA-rescuable NTDs, we show that RA or its precursors equall

Dynamic principles of concentration buffering through liquid-liquid phase separation.

Living systems must maintain robust biochemical function despite fluctuations that span a wide range of timescales. Biomolecular condensates formed by liquid-liquid phase separation (LLPS) have been shown to buffer concentration fluctuations, but the principles governing their dynamic regulation remain unclear. We address this by probing the response of LLPS to oscillatory perturbations that mimic fluctuations across different timescales, establishing the first systematic frequency-domain analys

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTART&#xc9;): a multicentre, phase 3, open-label, non-inferiority, randomised